Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb Company (BMY)
NYSE:BMY
BMY Stock Chart & Stats
$62.33
-$0.69(-1.21%)
At close: 4:00 PM EST
$62.33
-$0.69(-1.21%)
Day’s Range― - ―
52-Week Range$42.52 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)12.94M
Market Cap
$123.70B
Enterprise Value$160.62B
Total Cash (Recent Filing)$10.67B
Total Debt (Recent Filing)$47.14B
Price to Earnings (P/E)15.6
Beta0.26
Next Earnings
Apr 30, 2026EPS Estimate
1.45Next Dividend Ex-DateN/A
Dividend Yield4.84%
Share Statistics
EPS (TTM)1.26
Shares Outstanding2,036,473,800
10 Day Avg. Volume13,723,822
30 Day Avg. Volume12,940,571
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue3.33
Enterprise Value/Gross Profit4.93
Enterprise Value/Ebitda11.04
Forecast
1Y Price Target
$62.06Price Target Upside-0.44% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)6.24
Revenue Forecast (FY)$46.61B
Bulls Say, Bears Say
Bulls Say
Commercial LaunchesRevenue and adjusted EPS beats driven by broad commercial momentum and growing uptake of Reblozyl, Breyanzi and Camzyos indicate that new launches can meaningfully offset declines in legacy products.
Pricing And GuidanceOne-time US pricing adjustments that removed accumulated rebates and certain penalties materially improved Eliquis revenue assumptions and lifted company guidance, supporting stronger near-term cash generation.
Regulatory PathwayFDA acceptance of an NDA for iberdomide using minimal residual disease and breakthrough therapy designation strengthens the drug's path to approval and could accelerate market access if confirmatory data support the surrogate endpoint.
Bears Say
Clinical Timing And Approval UncertaintyConcentration of pivotal readouts and the need for confirmed progression-free survival or overall survival improvements to convert accelerated approvals create execution and regulatory risk that may keep valuation constrained until definitive results are produced.
Patent And Generic RiskForecasted loss of exclusivity and upcoming generic competition for key medicines represent a significant revenue headwind that could materially reduce long-term sales once generics enter major markets.
Safety And TolerabilitySelection of a low iberdomide dose amid neutropenia observations in earlier studies raises tolerability concerns that could limit dosing flexibility, clinical benefit and commercial adoption if adverse events persist.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb Company’s price range in the past 12 months?
Bristol-Myers Squibb Company lowest stock price was $42.52 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb Company’s market cap?
Bristol-Myers Squibb Company’s market cap is $123.70B.
When is Bristol-Myers Squibb Company’s upcoming earnings report date?
Bristol-Myers Squibb Company’s upcoming earnings report date is Apr 30, 2026 which is in 55 days.
How were Bristol-Myers Squibb Company’s earnings last quarter?
Bristol-Myers Squibb Company released its earnings results on Feb 05, 2026. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.226 by $0.034.
Is Bristol-Myers Squibb Company overvalued?
According to Wall Street analysts Bristol-Myers Squibb Company’s price is currently Overvalued.
Does Bristol-Myers Squibb Company pay dividends?
Bristol-Myers Squibb Company pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 4.84%. See more information on Bristol-Myers Squibb Company dividends here
What is Bristol-Myers Squibb Company’s EPS estimate?
Bristol-Myers Squibb Company’s EPS estimate is 1.45.
How many shares outstanding does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb Company has 2,036,473,800 shares outstanding.
What happened to Bristol-Myers Squibb Company’s price movement after its last earnings report?
Bristol-Myers Squibb Company reported an EPS of $1.26 in its last earnings report, beating expectations of $1.226. Following the earnings report the stock price went up 3.297%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb Company?
Currently, no hedge funds are holding shares in BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$62.06 (-0.44% Downside)
$62.06 (-0.44% Downside)
Blogger Sentiment
Bullish
BMY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.66%
12-Months-Change
Fundamentals
Return on Equity
40.53%
Trailing 12-Months
Asset Growth
-2.77%
Trailing 12-Months
Company Description
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
BMY Company Deck
BMY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.View all BMY earnings summariesBMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$62.06
▼(-0.44% Downside)
Technical Analysis
Ownership Overview
0.05% Insiders
19.69% Mutual Funds
6.15% Other Institutional Investors
47.30% Public Companies and Individual Investors